Latest News

STAT Plus: Careful stagecraft at Biogen’s big Alzheimer’s reveal cloaked deep divisions

SAN DIEGO — A Biogen executive had just finished presenting slides on the company’s resurrected Alzheimer’s drug at a medical meeting here on Thursday, and now it was time for the panel of experts up on stage to weigh in on whether they found the data convincing.

They did. In fact, they positively gushed. One of the experts called the data “exhilarating.” Another deemed it “a hugely important result.” A third heralded “a milestone achievement for our field.”

Continue to STAT Plus to read the full story…

Source link

Related posts

‘Response to therapy with TNFi is gender specific’


What Does a Self-Quarantine Look Like?


Glitazone Treatment and Incidence of Parkinson's Disease among People with Diabetes: A Retrospective Cohort Study


This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More

Privacy & Cookies Policy


COVID-19 (Coronavirus) is a new illness that is having a major effect on all businesses globally LIVE COVID-19 STATISTICS FOR World